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ABSTRAK
Tujuan: untuk mengevaluasi efektivitas terapi enhanced external counterpulsation (EECP) dalam 
memperbaiki kapasitas fungsional pasien gagal jantung kronik (GJK). Metode: uji klinik acak tersamar ganda 
dilakukan terhadap 99 pasien GJK yang menjalani terapi EECP di Klinik Jantung Jade, Manado pada periode 
waktu Januari 2014-Juni 2015. Pasien dibagi menjadi 2 kelompok dimana 49 pasien mendapatkan terapi sham 
EECP dan 50 pasien mendapatkan terapi EECP. Semua pasien GJK dilakukan latihan jalan 6 menit (LJ6M) 
sebelum dan sesudah menjalani terapi EECP. Hasil: karakterisitik dasar pasien GJK tidak ditemukan adanya 
perbedaaan bermakna antara kedua kelompok. Hasil LJ6M sebelum terapi pada kelompok sham EECP ditemukan 
30 pasien (61,2%) dengan jarak tempuh <300 meter sedangkan pada kelompok yang dilakukan terapi EECP 
sebesar 34 pasien (68%), p=0,24. Pasca terapi EECP ditemukan 33 pasien (67,3%) dengan jarak tempuh <300 
meter pada kelompok sham EECP, sedangkan pada kelompok terapi EECP hanya 1 pasien (2%), p<0,01. Jarak 
tempuh pada kelompok sham sebelum terapi adalah 252,65 (SD 97,55) meter dan pada kelompok EECP 243,65 
(SD 86,96) meter; p=0,18. Pada kelompok EECP jarak tempuh LJ6M sebelum dilakukan terapi adalah sebesar 
256,88 (SD 85,56) meter dan sesudah terapi EECP jarak tempuhnya menjadi sebesar 449,46 (SD 92,08) meter; 
p<0,01. Kesimpulan: terapi EECP efektif dalam memperbaiki kapasitas fungsional pada pasien GJK.
Kata kunci: gagal jantung kronis, latihan jalan 6 menit, terapi enhanced external counterpulsation.
ABSTRACT
Aim: to investigate the efficacy of enhanced external counterpulsation (EECP) therapy to improve functional 
capacity in patients with chronic heart failure (CHF). Methods: a double-blind random clinical trial was 
performed in 99 patients with CHF who had received EECP therapy at Jade Cardiovascular Clinic, Manado, 
North Sulawesi, Indonesia between January 2014 and June 2015. Subjects were categorized into 2 groups, i.e. 49 
subjects had sham EECP therapy and 50 subjects had EECP therapy. All subjects performed six-minute walking 
test (6MWT) before and after receiving EECP therapy. Results: there was no significant difference between 
both groups regarding the basic characteristics of patients with CHF. The 6MWT result before EECP therapy 
showed that there were 30 patients (61.2%) with walk distance of <300 meter in the sham EECP group; while 
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INTRODUCTION
Heart failure is still a major health problem. 
The incidence of heart failure is increasing from 
1.5-4% to 6.7-9.9% in developing countries.1-3 In 
patients with chronic heart failure (CHF), there is 
a reduced left ventricular ejection fraction (LVEF), 
cardiomegaly, and increased left ventricular end 
diastolic pressure (LVEDP), which will produce 
clinical manifestations such as short of breath 
(dyspnea), fatigue, insomnia, easily awake 
due to shortness of breath that result in limited 
daily physical activity and impair the functional 
capacity of patients.3-6
In patients with CHF, functional capacity 
is a method to evaluate patient’s ability to 
perform daily activity, which can be measured 
by performing six-minute walking test (6MWT). 
The 6MWT is a simple test, which is easily 
performed and it is usually utilized to evaluate 
functional exercise capacity, walking capacity 
and the effectiveness of treatment in patients 
with CHF.4-9
Various treatment methods have been 
performed to increase survival and improve 
quality of life for patients with chronic heart 
disease. One of those various methods that 
have been applied recently in the last decade 
is enhanced external counterpulsation (EECP) 
therapy. The therapy is used to improve 
contractility of myocardium and increase 
stroke volume in addition to its angiogenesis 
and atherogenesis effect as well as developing 
new collateral circulation. Enhanced external 
counterpulsation is a treatment of choice for 
patients with CHF who still have symptoms of 
fatigue after receiving optimal pharmacological 
treatment and for those who are not eligible for 
having revascularization treatment.10-14
Some studies show that EECP treatment does 
not provide significant improvement effect on 
increased left ventricular ejection fraction or on 
exercise tolerance; however, some studies on the 
effects of EECP therapy have recently provided 
evidence about its beneficial effect for patients 
with angina pectoris and heart failure.10-12,15-17 
However, there is very limited data about EECP 
studies on chronic heart failure. The 6MWT 
was performed to evaluate their functional 
capacity. Our study was aimed to evaluate the 
effectiveness of EECP treatment to improve 
functional capacity in patients with CHF. 
METHODS
Our study was designed to evaluate functional 
capacity using six-minute walking test in patients 
with CHF, on those who had received EECP 
therapy or who only had sham EECP therapy. The 
study was conducted at the Jade Cardiovascular 
Clinic, Manado, North Sulawesi, Indonesia 
between January 2014 and June 2015. The target 
population in our study was all patients with 
chronic heart failure; while the study population 
was patients with chronic heart failure who had 
treatment at the Jade Cardiovascular Clinic, 
Manado Siloam Hospital, Manado Adventist 
Hospital and Prof. Dr. R.D. Kandou General 
Hospital, Manado. The subjects of our study 
were all patients with CHF who were eligible as 
well as those who had met the inclusion criteria 
and who were willing to participate in our study. 
The inclusion criteria of our study were 
patients with: 1) age between 25 and 79 years; 
2) mild to moderate symptomatic chronic heart 
failure (NYHA functional class I-II) with the 
following etiology: ischemic heart disease, 
hypertension heart disease, coronary heart 
in the group receiving EECP therapy, we found 34 patients (68%); p=0.24. Post-EECP therapy, there were 33 
patients (67.3%) with walk distance of <300 meters in EECP sham group; while in the group receiving EECP 
alone, there was only 1 patient (2%); p <0.01.The 6MWT walk distance in sham group before EECP therapy 
was 252.65 (SD 97.55) meters and it was 243.65 (SD 86.96) meters following the EECP therapy; p=0.18. In 
EECP group, the 6MWT walk distance before therapy was 256.88 (SD 85.56) meters and after EECP therapy 
the walk distance was 449.46 (SD 92.08) meters; p<0.01. Conclusion: EECP therapy is effective to improve 
functional capacity in patients with CHF.
Key words: chronic heart failure, six-minute walk test, enhanced external counterpulsation (EECP) therapy.
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disease or acute coronary syndrome; 3) certain 
echocardiography result, i.e. the difference 
between end diastolic volume and end systolic 
volume divided with end diastolic volume was 
<40%; 4) chronic heart disease who had received 
standard therapy according to the heart failure 
national guideline for at least one month before 
participating in our study; 5) willingness to 
participate in the study and signed the informed 
consent form. 
The exclusion criteria were those with:11,15,16 
1) severe heart valve damage; 2) acute coronary 
syndrome at least <6 weeks prior to the study; 3) 
major arrhythmia that significantly can interfere 
the EECP instrument such as atrial fibrillation, 
extra systole of more than six times per minute; 
4) heart catheterization <2 weeks prior to the 
study; 5) history of bypass surgery <3 months 
and history of coronary stent implant less than 
6 months prior to the study and peripartum 
cardiomyopathy; 6) implantable cardioverter 
defibrillator instrument; 7) pregnancy and 
breastfeeding; 8) intermittent claudication; 9) 
uncontrolled blood pressure of >180/110 mmHg; 
10) deep vein thrombosis, thrombophlebitis, 
pulmonary embolism or aortic aneurysm; 11) 
other medical, legal or social condition that 
may affect the patients’ judgment in giving their 
informed consent or when participating the study. 
The drop out criteria were patients who did not 
complete EECP/Sham EECP therapy either 
with or without reason including those who had 
cardiovascular or severe side effect as well as 
those who had lost their interest in our study.
Intervention
The EECP instrument consists of 3 pairs of 
pneumatic cuff, which were applied to lower 
extremities. The patients were treated for 1 hour 
daily for a total of 36 sessions in 7 weeks. Three 
sets of pneumatic cuff were applied to calves, 
lower and upper thigh and were sequentially 
inflated during the diastolic phase of the heart. 
Furthermore, an external pressure of 300 mmHg 
was applied during the diastolic phase for 
subjects in EECP therapy group; while those in 
sham EECP group only had 75 mmHg, enough 
to preserve the appearance and feel of an EECP 
application, but insufficient to alter measurably 
the patient’s blood pressure. All patients then 
performed the six-minute walking test. The test 
was conducted as indoor test in a straight corridor 
which had 30 meters length as recommended by 
the American Thoracic Society (ATS) guideline. 
Sample Size
Number of needed samples was calculated 
using statistical formula based on the difference 
of walking distance in six minutes between 
patients with and without EECP intervention. 
Confidence interval of 95% and statistical 
power of 80% were applied in the sample size 
calculation. Based on our previous clinical 
experience, the estimated Standard Deviation of 
walking distance was 90 meters and the minimal 
expected significant difference between both 
groups after intervention was 50 meters, thus the 
needed sample size is 50 subjects for each group.
There were 158 patients who had received 
optimal medical treatment were included in our 
study and after having screening test, 46 patients 
were excluded as 15 patients were not willing 
to participate in our study and 31 patients did 
not meet the inclusion criteria. The patients 
subsequently underwent further tests and filled 
the form about basic characteristics data for 
population study such as demography, risk 
factors for coronary heart disease, laboratory data 
on blood glucose and cholesterol level as well as 
echocardiography and medication.
Randomization and Blind
Our study was a double blind randomized 
clinical trial, in which the evaluator did not know 
about the category of subject groups. We did 
not know whether the patients with CHF were 
in the group receiving EECP or sham EECP 
therapy. Block randomization using concealed 
envelopes was then performed and the subjects 
were categorized into 2 groups, i.e. there were 
56 patients in the sham EECP group and other 56 
patients in the EECP therapy group. The study 
participants were recruited by the participating 
cardiologists following the study protocol. The 
test was carried out by 2 specific clinical nurses 
at the Jade Cardiovascular Clinic. During the 
treatment period, 7 patients were excluded from 
the sham EECP group; consisted of 4 patients that 
were dropped out since they could not complete 
the study, and 3 patients had cardiovascular 
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adverse events (rehospitalized); while in the 
EECP group, we found 6 patients who were not 
able to continue the study including 3 dropped 
out patients, 1 patient who had lost his interest 
to continue the study and 2 patients who had 
cardiovascular events (rehospitalized). There 
were 49 patients who completed EECP treatment 
in sham group and there were 50 patients in 
EECP group. Afterwards, all patients performed 
the six-minute walking test.
Statistical Analysis
Statistical analysis was performed for all 
outcomes including primary, secondary and 
safety outcomes. Data were processed using 
mean value (standard deviation) and were tested 
with unpaired mean difference (median). In 
order to evaluate the difference between EECP 
and sham EECP data, unpaired student T-test 
was used when the data in both groups showed 
normal distribution; when it did not show normal 
distribution, a Mann-Whitney ranks test was 
used. Alpha of 5% was used in interpreting 
statistical significance. The data of our study was 
analyzed using a computer software program of 
SPSS version 22.0.
Study Protocol 
Patients with CHF who were in stable 
condition of NYHA functional class I and II and 
who had received optimal treatment for coronary 
heart disease, including beta blocker, nitrate, 
aspirin and statin performed six-minute walking 
test and filled in the WHO-5 questionnaires. 
They were then randomly selected to receive 
EECP treatment or non-EECP treatment (i.e. only 
receiving optimal sham therapy to imitate EECP 
treatment). An evaluation was subsequently 
conducted in 6 weeks following the EECP 
treatment, both for EECP and sham EECP group 
by performing the six-minute walking test.
Our study was conducted in keeping with 
Helsinki declaration and was supported by ethical 
clearance. The ethical clearance was issued 
by ethic committee of Faculty of Medicine, 
University of Sam Ratulangi, Manado with 
registration number 014.01.06/11.2/018/2014. 
All patients were obliged to sign informed 
consent before participating in our study.
RESULTS
The study was conducted between January 
2014 and June 2015. Figure 1 shows a flow chart 
for participants in the study. Outcome measures 
of 6MWT were collected at baseline and after 
EECP therapy.
Based on the results of our study, we found 
that most of CHF patients in both groups were 
male and they were most frequently at the age of 
55-65 years. From the basic characteristic data 
of patients, we did not find significant difference 
between those in EECP group and those in sham 
EECP group as presented in Table 1.
Table 2 shows that there was no significant 
difference of pre-treatment six-minute walking 
test results between sham EECP and EECP 





















Figure 1. The participants’ flow diagram
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distance in EECP  group in which 98% subjects 
had significant statistical rate for walk distance 
of >300 meters (p<0.01); while in sham EECP 
group, we found no significant difference when 
compared to pre-EECP treatment.
There was no significant difference of the 
six-minute walking test results in the sham EECP 
group between before and after treatment (252.65 
[SD 97.55] vs. 243.65 [SD 86.96]; p=0.18). 
However, there was a significant increased 
result of six-minute walking test in EECP group 
(256.88 [SD 85.56] vs. 449.46 [SD 92.08]; 
p<0.01) as we can see in Table 3. Delta analysis 
after and before EECP of both group also shows 
significantly different (-9 [SD 67.68] vs 192.58 
[SD 87.45]; p<0.05).
DISCUSSION
The mechanism of action for EECP in 
alleviating symptoms of chronic angina has 
not been fully understood; however, the 
hemodynamic effect of EECP is basically the 
same with intra-aortic balloon pump (IABP), i.e. 
by reducing afterload and increasing coronary 
perfusion pressure through diastolic pressure in 
aortic root. At the initial phase of left ventricular 
diastolic, the sets of pneumatic cuff were 
subsequently inflated and applied to the calves, 
upper and lower thigh-one at a time. The inflated 
cuffs will cause arterial and venous compression 
of the lower extremities and pump the blood to 
superior part of the body, both to the aortic root 










Age (year),mean (SD) 62.43 (12.06) 60.54 (8.6)
Gender (male), n (%) 38 (77.6) 36 (72.0)
Weight (kg),mean (SD) 61.8 (11.74) 58.5 (12.02)
Height (cm),mean (SD) 162,6 (8.92) 160.4 (8.69)
BMI (kg/m2),mean (SD) 23.67 (3.48) 23.06 (4.10)
Cardiovascular Risk factor
Dyslipidemia, n (%) 34 (69.4) 34 (68.0)
Hypertension, n (%) 35 (70.1) 35 (71.4)
Smoking, n (%) 16 (32.7) 20 (49.0)
Diabetes mellitus,n (%) 13 (26.5) 14 (28.0)
Family predisposition, 
n (%)
14 (28.6) 8 (16.0)
Blood Parameters
Fasting glucose  
(mg/dL), mean (SD)
109.41 (42.52) 95.54 (32.60)
HbA1c, n (%) 6.83 (1.81) 6.18 (2.05)
Total cholesterol  
(mg/dL), mean (SD)
218.33 (74.16) 210.08 (49.61)
LDL cholesterol  
(mg/dL), mean (SD)
160.12 (33.94) 157.86 (49.16)
HDL cholesterol  
(mg/dL), mean (SD)
33.76 (8.46) 38.50 (8.18)
Triglycerides (mg/dL), 
mean (SD)




61.89 (9.18) 63.54 (8.66)
LVESD (mm),mean 
(SD)
50.47 (8.65) 51.96 (8.14)
LVEF (%), mean (SD) 32.69 (3.82) 31.88 (3.95)
Medications
Aspirin, n (%) 48 (97.9) 48 (96.0)
Statin, n (%) 48 (97.9) 49 (98.0)
b-blocker, n (%) 40 (81.6) 41 (82.0)
Ace Inhibitors/ARB,  
n (%)
44 (89.8) 45 (90.0)
Nitrates, n (%) 41 (83.7) 43 (86.0)
Exercise tolerance 6 
MWT (m), mean (SD) 252.65 (97.55) 256.88 (85.56)
LVEDD = Left ventricular end diastolic diameter; LVESD 
= Left ventricular end-systolic diameters;LVEF = Left 
ventricular ejection fraction; LDL = Low density lipoprotein
Table 2. Comparison of 6 MWT distance between Sham 
EECP group and EECP group before and after EECP 
therapy
Variables
6 MWT Distance ρ 
value≤300 m >300 m
Before Intervention, n (%)
 - Sham group 
(n=49)
30 (61.2) 19 (38.8) 0.24*
 - EECP group 
(n=50)
34 (68.0) 16 (32.0)
After Intervention, n (%)
 - Sham group 
(n=49)
33 (67.3) 16 (32.7) <0.01*
 - EECP group 
(n=50) 1 (2.0) 49 (98.0)
*Chi square test
(61.2% vs. 68.0%) or for walk distance of >300 
meters (38.8% vs. 32.0%); p=0.24. Table 2 
also shows results on post-six-minute walking 
test and we found significant increased walking 
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and cava vein. The blood pumping may produce 
increased aortic diastolic pressure, which may 
push strong and oxygen-rich blood toward the 
heart and increasing the perfusion pressure of 
coronary artery.11,12
In chronic heart failure, reduced vascular 
shear stress occurs persistently, which may 
worsen endothelial dysfunction. The EECP will 
produce pulsatile blood circulation, which will 
increase Endothelial shear stress (ESS) leading 
to improved endothelial function, reduced pro-
inflammatory cytokines, lower macrophage 
accumulation and complement activation and 
reduced vascular inflammation.17 In general, 
the mechanism of action of EECP is to reduce 
afterload and lower myocardial oxygen demand. 
EECP increases coronary blood flow and 
promotes myocardial collateralization through 
the development of collateral blood vessels, 
arteriogenesis and angiogenesis. Increased blood 
flow and ESS can improve endothelial function, 
vasodilatation and myocardial perfusion.11
Recently, there are studies about EECP 
therapy in patients with heart failure, which 
demonstrate that the therapy is beneficial in 
improving exercise capacity, quality of life and 
functional status with a small number of side 
effects. A study by Michaels et al evaluated the 
advantages of EECP on aortic, intracoronary 
and left ventricular hemodynamic with left heart 
catheterization. The study concludes that EECP 
has the same effect with IABP. EECP has also 
been known as a procedure to increase venous 
return and contributes to increased cardiac output 
without any increase in heart rate. Michael et al 
found that increased preload during EECP has 
a balance effect on reduced afterload, which 
gives neutral effect on myocardial efficiency.18 
Masuda et al19 demonstrate that EECP may 
induce the release of angiogenesis factors. 
ANP and BNP levels were found lower after 
EECP therapy and NO (nitrite oxide) level 
was higher during rest. Masuda et al19 show 
that there is improved coronary vasodilatation 
and myocardial perfusion following the EECP 
therapy. The PEECH (Prospective Evaluation 
of EECP in Heart Failure) study in patients 
with heart failure (class II and III NYHA 
classification) indicate that EECP therapy can 
increase exercise duration, improve NYHA 
functional status and quality of life.16 Results of 
“MUST-EECP” (Multicenter Study of Enhanced 
External Counterpulsation) show that EECP 
therapy is safe and effective for patients with 
chronic heart failure.20
In our study, six-minute walking test 
performed in all patients after they completed 
the EECP/ sham EECP treatment. The six-minute 
walking test is an indicator and predictor for 
health and physical ability status. According to 
the American Thoracic Society (ATS), six-minute 
walking test is able to measure various capacity 
level, such as the capacity of cardiovascular 
and respiratory system, hemodynamic changes, 
systemic and peripheral circulation as well as 
neuromuscular metabolism.21
The six-minute walking test in our study 
showed high significance difference (Table 2 
and 3) between EECP group and sham EECP 
group at the end of our observation (p<0.01). 
The increased walking distance of six-minute 
test found in patients who had received routine 
EECP therapy indicates that there is increased 
functional capacity. Improved functional capacity 
post-EECP is associated with a significant and 
persistent increase of exercise capacity through 
increased oxygen uptake, increased tolerance and 
better exercise duration.11,15,22 In our study, there 
were 49 patients (98%) who could have >300 m 
walking distance following the EECP therapy 
Table 3. Comparison of 6 MWT distance between Sham EECP group and EECP group before and after EECP 
therapy
Variables Before After D Analysis after - before
6 MWT distance, mean (SD)
Sham group 252.65 (97.55) 243.65 (86.96) -9 (67.68)
EECP group 256.88 (85.56) 449.46 (92.08) 192.58 (87.45)*
*Mann Whitney Rank test; # p<0.01
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compared to those in sham EECP group (32.7%) 
as seen in Table 2. EECP therapy is similar to a 
physical exercise and gives effects as if we are 
running since it increases blood flow and shear 
stress of arterial muscular layer in the lower 
extremities. Continuous movement will increase 
NO release from endothelial cells and produce 
vasodilatation. Increased NO release in coronary 
artery during EECP therapy has been correlated 
to improve reservoir of coronary blood flow and 
endothelial function associated with increased 
myocardial perfusion and exercise tolerance. 
Another study has also demonstrated that 
EECP therapy increases NO release to improve 
peripheral endothelial function and vaso-
relaxation of the smooth muscle.23 Improved 
endothelial function is associated with improved 
heart function and symptoms experienced by the 
patient.24
Increased walking distance in six-minute 
walking test (>300 m) in EECP group indicates 
improved functional capacity in patients with 
heart failure. This result has been proved in our 
study as seen in Table 3. There is improvement 
of walking distance in EECP group compare 
with sham group. It was shown that there is a 
significant difference of delta analysis after and 
before EECP between two groups. A study by 
O’Connor et al25 for patients with chronic heart 
failure who also underwent six-minute walking 
test also demonstrated a great improvement 
of walking distance after physical exercise in 
3-month observation. A number of patients 
demonstrated peak increase of oxygen uptake.25,26 
Improved functional capacity as shown by 
increased walking distance of six-minute 
walking test is a beneficial EECP effect and it 
contributes to lower cardiovascular incidence, 
less recurrent hospitalization and lower mortality 
rate of patients with CHF.
This study has limitation due to the fact that 
some of participants from both groups had to 
be dropped out of the study. However, despite 
its limitation, the findings of this study could be 
generalized for CHF patients with NYHA class 
I-II that can be improved their functional capacity 
using EECP treatment.
CONCLUSION
EECP therapy is safe and effective. It 
brings beneficial effects on improved quality 
of life in patients with chronic heart failure as 
demonstrated by increased walking distance in 
six-minute walking test. 
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